Penny Players:
MTCH DD
| Next | Respond | Remove Navigation
To: Logistics (61 )
From: B.MCVEE Wednesday, May 6 1998 9:38PM ET
Reply # of 79
MTCH....
Could be interesting
Overview
Meditech Pharmaceuticals, Inc.
EXECUTIVE SUMMARY
Meditech Pharmaceuticals, Inc. (Meditech or the Company) is a publicly
traded company, focusing in the areas of research, development, and
marketing in the biomedical industry. Meditech's R & D efforts are
concentrated in the area of anti-viral and anti-microbial drugs for
ethical, over-the-counter, veterinary, and agricultural use. The Company
was organized in 1983.
Patents
Five U.S. patents totalling 59 claims have been granted for anti-viral
and anti-bacterial uses of its drug MTCH-24'. In addition, three
Canadian patents were issued in 1988 and 1989 granting 18 anti-viral
claims, and an Italian patent was granted in November 1988 on Viraplex
for use as a Herpes simplex treatment. Other patents have been allowed
in nine countries.
Management
Meditech's management, directors, and advisers have significant
experience in biomedical research, product marketing, and consumer
products distribution.
Products
Viraplex promises to prove useful in the treatment of orofacial and
genital Herpes simplex. The drug is in Phase III clinical trials for
safety and efficacy in humans. The genital Herpes portion of the trials
has been completed, and preliminary analysis shows Viraplex to be safe
and effective. MTCH-24 has been successfully tested in the laboratory
against the Herpes simplex virus, cytomegalovirus, Epstein-Barr virus,
rotavirus, and other enveloped viruses. It also has been shown effective
in laboratory tests against gram-positive bacteria, including
staphylococcus and streptococcus, and certain fungi, including Candida
albicans. MTCH-24 has also demonstrated effectiveness in laboratory and
field tests against Xanthomonas campestris, the organism which causes
citrus canker, and against Aflatoxin, a major problem in stored corn and
other grains.
------------------------------------------------------------------------
-------- |
